Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

JanWillem Duitman

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
ERJ Open Research|February 7, 2019
Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debateC Arnold Spek, JanWillem Duitman
The European Respiratory Journal|June 13, 2020
Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?C Arnold Spek, JanWillem Duitman
American Journal of Respiratory and Critical Care Medicine|March 17, 2023
PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?C Arnold Spek, JanWillem Duitman
Matrix Biology : Journal of the International Society for Matrix Biology|March 9, 2018
The impaired proteases and anti-proteases balance in Idiopathic Pulmonary FibrosisAwen Menou, JanWillem Duitman, Bruno Crestani
Biochemistry and Biophysics Reports|November 9, 2017
Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent mannerMaaike Waasdorp, JanWillem Duitman, C Arnold Spek
Biomedicines|February 25, 2022
Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent MannerC Arnold Spek, Hella L Aberson, JanWillem Duitman
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 10, 2019
Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathyMaaike Waasdorp, Sandrine Florquin, JanWillem Duitman, et al.
Oncotarget|May 19, 2018
Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in miceMaaike Waasdorp, JanWillem Duitman, Sandrine Florquin, et al.
Scientific Reports|September 14, 2016
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in miceMaaike Waasdorp, JanWillem Duitman, Sandrine Florquin, et al.
Journal of Clinical Medicine|September 29, 2019
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?JanWillem Duitman, Tom van den Ende, C Arnold Spek
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
ERJ Open Research|February 7, 2019
Is idiopathic pulmonary fibrosis a cancer-like disease? Transcriptome analysis to fuel the debateC Arnold Spek, JanWillem Duitman
The European Respiratory Journal|June 13, 2020
Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?C Arnold Spek, JanWillem Duitman
American Journal of Respiratory and Critical Care Medicine|March 17, 2023
PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?C Arnold Spek, JanWillem Duitman
Matrix Biology : Journal of the International Society for Matrix Biology|March 9, 2018
The impaired proteases and anti-proteases balance in Idiopathic Pulmonary FibrosisAwen Menou, JanWillem Duitman, Bruno Crestani
Biochemistry and Biophysics Reports|November 9, 2017
Plasmin reduces fibronectin deposition by mesangial cells in a protease-activated receptor-1 independent mannerMaaike Waasdorp, JanWillem Duitman, C Arnold Spek
Biomedicines|February 25, 2022
Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent MannerC Arnold Spek, Hella L Aberson, JanWillem Duitman
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 10, 2019
Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathyMaaike Waasdorp, Sandrine Florquin, JanWillem Duitman, et al.
Oncotarget|May 19, 2018
Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in miceMaaike Waasdorp, JanWillem Duitman, Sandrine Florquin, et al.
Scientific Reports|September 14, 2016
Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in miceMaaike Waasdorp, JanWillem Duitman, Sandrine Florquin, et al.
Journal of Clinical Medicine|September 29, 2019
Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?JanWillem Duitman, Tom van den Ende, C Arnold Spek
Pageof 6